Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.3%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3.8% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 37 million units today, marking 15 consecutive trading days of inflow, with the latest scale reaching 980 million yuan, a historical high [1] - CITIC Securities believes that many innovative drug assets in China have gradually entered the global spotlight, with both the amount and value of Business Development (BD) authorization continuing to rise [1] Group 2 - The innovative drug sector is experiencing a valuation recovery driven by clinical data and strengthened BD expectations, leading to a growing recognition of the global value of Chinese assets [1]
标的指数涨超4%，恒生创新药ETF（159316）今日获3700万份净申购
Mei Ri Jing Ji Xin Wen·2025-08-05 22:59